Where the power of nature meets the logic of science for the betterment of health. More »
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property....
|02/16/18||ChromaDex Chairman Stephen Allen Will Retire from Board of Directors|
|IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age is announcing that on February 13, 2018, Steve R. Allen, the Chairman of the Board, informed the Company that he intends to retire from the Board of Directors at the end of his current term after four years of service. Accordingly, Mr. Allen will not stand for re-election as a director at Chr... |
|02/12/18||ChromaDex Corporation Reports Preliminary 2017 Results |
|Fourth Quarter 2017 Net Revenues Expected to Increase by 69% to Approximately $7.5 Million
IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results.
Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of appr... |
|02/08/18||National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease|
|Results of the Collaborative Study Provide Strong Preclinical Support for Nicotinamide Riboside Research in Alzheimer’s Patients
IRVINE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the results from its collaborative research agreement with the NIA and NIH which appear in the Feb. 5, 2018, issue of Proceedings of the National Academy of Sciences (PNAS) ... |
There are currently no events scheduled.
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed.|